A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)

Condition:   Bladder Cancer Interventions:   Biological: Toca 511;   Drug: Toca FC (extended-release formulation of flucytosine) Sponsor:   Tocagen Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials